BIBW-2992 (AFATINIB)
$80.00 – $395.00
Conditions of optimal IL-2 Protein performance should be determined experimentally by the investigator.
- Details & Specifications
- References
- More Offers
| Catalog No. | APIM050115 |
|---|---|
| Product Name | BIBW-2992 (AFATINIB) |
Description
BIBW2992 (Afatinib) is an ATP-competitive, small molecule irreversible inhibitor for EGFR/HER2, displaying inhibitory potency against EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2, with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Reference:
1. Li, D. et al., BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene 2008, 27 (34), 4702-4711.
2. Minkovsky, N. et al., BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors”. Curr Opin Investig Drugs (December 2008), 9 (12), 1336–46.
APIM050115: BIBW-2992 (AFATINIB)
CAS No.: 850140-72-6.
Molecular Formula: C24H25ClFN5O3 • 0.7H2O.
Molecular Weight: 498.6.
Purity: >99.5% chem and optical purity (HPLC and Chiral HPLC).
QC: HPLC-MS, 1HNMR, Chiral HPLC and Quatitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
